Top Page
OKYO Pharma Limited Sponsored ADR
(NASDAQ:OKYO)
OKYO Pharma Limited Sponsored ADR (OKYO) vs. SPDR S&P 500 ETF (SPY)
OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model
OKYO Pharma Limited Sponsored ADR Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.17K | -2.56K | -3.87K | -3.80K | -2.42K | -13.09K |
| EBITDA | -9.58M | -7.08M | -15.75M | -13.18M | -6.21M | -3.35M |
| Net Income | -4.61M | -4.71M | -16.83M | -13.27M | -5.43M | -3.35M |
Balance Sheet | ||||||
| Total Assets | 4.64M | 3.68M | 1.54M | 5.20M | 4.30M | 7.09M |
| Cash, Cash Equivalents and Short-Term Investments | 4.22M | 1.56M | 826.85K | 4.05M | 2.70M | 6.89M |
| Total Debt | 185.79K | 0.00 | 0.00 | 2.22M | 0.00 | 98.76K |
| Total Liabilities | 8.06M | 9.23M | 7.42M | 7.26M | 1.35M | 1.77M |
| Stockholders Equity | -3.42M | -5.55M | -5.88M | -2.05M | 2.95M | 5.32M |
Cash Flow | ||||||
| Free Cash Flow | -3.10M | -1.81M | -9.49M | -7.70M | -5.47M | -1.61M |
| Operating Cash Flow | -3.10M | -1.81M | -9.49M | -7.70M | -5.47M | -1.60M |
| Investing Cash Flow | -1.21K | -1.21K | 0.00 | -5.92K | -1.67K | -18.11K |
| Financing Cash Flow | 6.42M | 2.66M | 6.21M | 9.32M | 2.15M | 7.83M |
OKYO Pharma Limited Sponsored ADR Technical Analysis
OKYO Pharma Limited Sponsored ADR Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $435.01M | -9.89 | -47.85% | ― | ― | -19.69% | |
54 Neutral | $167.18M | -1.26 | -85.93% | ― | ― | -60.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $92.62M | -0.59 | -209.00% | ― | ― | 40.22% | |
49 Neutral | $59.59M | -0.99 | -76.44% | ― | -10.03% | 11.06% | |
42 Neutral | $85.79M | -13.56 | ― | ― | ― | ― |
OKYO Pharma Limited Sponsored ADR Corporate Events
On February 23, 2026, OKYO Pharma announced that an abstract detailing the first-in-human study of its lead candidate urcosimod in neuropathic corneal pain has been accepted for presentation at the ARVO 2026 Annual Meeting in Denver, to be held May 3–7, 2026. Chief Scientific Officer Raj Patil, Ph.D., will present Phase 2a proof-of-concept data showing clinically meaningful reductions in pain and quality-of-life improvements, with signals suggesting potential restoration of corneal nerve structure.
Neuropathic corneal pain is a chronic, debilitating ocular condition with no FDA-approved therapies, leaving patients reliant on off-label treatments that often provide limited benefit. Building on the positive Phase 2a NCP results and prior pain-reduction data in dry eye disease, OKYO plans to advance urcosimod into a larger, approximately 150-patient multicenter Phase 2b/3 trial in the coming months, a step that could strengthen its position in ophthalmology and potentially address a major unmet medical need if later-stage results are successful.
The most recent analyst rating on (OKYO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On February 12, 2026, OKYO Pharma Limited signed an underwriting agreement with Piper Sandler & Co. for an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, with a 30-day option for underwriters to purchase up to 1,622,250 additional shares. The deal is expected to raise about $20 million in gross proceeds, with closing targeted for February 17, 2026, and the funds earmarked for clinical development, general corporate purposes, and working capital, potentially strengthening OKYO’s funding base for its pipeline and operations.
The offering was launched under an effective Form F-3 shelf registration statement declared effective by the U.S. Securities and Exchange Commission on February 10, 2026, supported by customary legal opinions and indemnification provisions. OKYO also furnished an updated investor presentation in February 2026, providing the market with refreshed information on its strategy and programs as it accesses the capital markets through this equity raise.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On February 12, 2026, OKYO Pharma announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, expected to raise about $20 million in gross proceeds. The company also granted the underwriter a 30-day option to buy up to 1,622,250 additional shares, which would lift gross proceeds to roughly $23 million before expenses if fully exercised.
OKYO plans to deploy the net proceeds to advance clinical development of its pipeline, including its lead candidate for neuropathic corneal pain, as well as for general corporate purposes and working capital. The deal, managed solely by Piper Sandler and expected to close around February 17, 2026, strengthens the company’s funding base as it prepares for a pivotal Phase 2b/3 trial, potentially enhancing its position in the niche ocular pain and inflammatory eye disease market.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On February 12, 2026, OKYO Pharma announced plans for an underwritten public offering of its ordinary shares, with all shares to be issued and sold by the company. The company also expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares sold at the public offering price, subject to market conditions and final terms.
Piper Sandler & Co. has been appointed sole book-running manager for the offering, which is being made under OKYO’s recently declared-effective shelf registration statement on Form F-3. OKYO intends to use the net proceeds primarily to fund clinical development of its product candidates, including advancing urcosimod, as well as for general corporate purposes and working capital, potentially strengthening its financial position as it moves into later-stage trials in ocular indications.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On February 11, 2026, OKYO Pharma announced it has shifted its At-The-Market equity offering facility to Leerink Partners LLC, replacing its prior arrangement with B. Riley Securities Inc. Leerink, a healthcare-focused investment bank, will act as exclusive sales agent, earning a 3.0% commission on gross proceeds from any common shares sold into the market under the program.
Management said the move is intended to enhance financial flexibility as the company advances its clinical pipeline, including the planned Phase 2b/3 study of lead candidate urcosimod for neuropathic corneal pain. By keeping an ATM facility in place, OKYO can raise capital opportunistically at prevailing market prices with potentially less market disruption, supporting ongoing development and corporate objectives without committing to a large, fixed equity raise.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On February 10, 2026, OKYO Pharma Ltd entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market equity program allowing the company to sell up to $50 million of its ordinary shares from time to time on Nasdaq or other U.S. trading venues. The shares will be issued under an effective Form F-3 shelf registration declared effective the same day, with Leerink Partners acting as sales agent or principal, earning a 3% commission on gross sales and having the ability, along with the company, to suspend or terminate sales at any time, providing OKYO with flexible access to incremental equity capital while diluting existing shareholders as new shares are sold.
Under the arrangement, OKYO controls the timing, volume, price floors and daily caps for any sales, and is not obligated to sell any minimum amount of stock, leaving the ultimate size and proceeds of the program undetermined. The agreement includes customary representations, covenants, indemnification provisions and reimbursement of specified expenses for Leerink Partners, positioning OKYO to tap the market opportunistically as funding needs and market conditions dictate without undertaking a single, large equity issuance.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
OKYO Pharma announced on February 10, 2026, that it has appointed Flavio Mantelli, MD, PhD, as Chief Medical Officer, adding a prominent ophthalmology specialist with deep expertise in corneal and ocular surface diseases. Mantelli previously led the clinical development, FDA approval and global medical strategy of Oxervate, a corneal disease therapy that reached more than $1 billion in sales in 2024 and is regarded as a benchmark orphan drug success in ophthalmology.
In his new role, Mantelli will direct OKYO’s clinical and regulatory strategy, including advancing urcosimod into planned trials for neuropathic corneal pain and additional orphan indications. The hire, which follows the recent appointment of CEO Robert Dempsey, further strengthens OKYO’s leadership as it prepares a roughly 150-patient Phase 2b/3 study of urcosimod in neuropathic corneal pain, an area with no FDA-approved treatments and high unmet medical need.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On January 30, 2026, OKYO Pharma reported interim results for the six months ended September 30, 2025, highlighting a series of clinical, regulatory and financial milestones that advance its lead drug urcosimod for neuropathic corneal pain. Over the period, the company generated positive long-term stability data for urcosimod, secured FDA Fast Track Designation for its use in NCP, and reported strong topline Phase 2 proof‑of‑concept data in 18 patients, with 75% of per‑protocol participants achieving more than 80% pain reduction on the Visual Analogue Scale after 12 weeks, while also outlining a registration strategy that includes a planned 150‑patient multicenter Phase 2b/3 trial. OKYO supplemented this clinical progress with $1.9 million in non‑dilutive funding in July 2025 and improved its balance sheet to $4.2 million in cash and $4.6 million in total assets as of the period end, while narrowing its comprehensive loss to $3.0 million from $3.2 million a year earlier. In early 2026 the company further strengthened its leadership and regulatory position by appointing ophthalmology industry veteran Robert J. Dempsey as chief executive officer, transitioning former CEO Gary S. Jacob to chief development officer, and securing FDA alignment in a January 28, 2026 Type C meeting on the design, endpoints, and chemistry, manufacturing and controls strategy for the planned Phase 2b/3 urcosimod trial, in a move that de‑risks its pivotal program and positions OKYO as an emerging player in addressing a major unmet need in ophthalmology.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On January 30, 2026, OKYO Pharma announced that Phase 2 proof-of-concept efficacy and safety data for its lead candidate urcosimod in neuropathic corneal pain have been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting in Washington, DC, scheduled for April 11, 2026. The acceptance, following a competitive review process, provides scientific validation and visibility for the positive pain-reduction signals and corneal nerve health trends seen in OKYO’s recently completed Phase 2 NCP trial, supporting the company’s strategy to advance urcosimod into a larger 150-patient Phase 2b/3 study in the first half of 2026 and potentially strengthen its positioning in the underserved market for NCP, which currently lacks FDA-approved therapies.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On January 28, 2026, OKYO Pharma announced it had held a successful Type C meeting with the U.S. Food and Drug Administration regarding the planned Phase 2b/3 human clinical trial of urcosimod for neuropathic corneal pain. The FDA confirmed that the proposed primary endpoint of Visual Analogue Scale pain reduction at Week 12 is clinically meaningful, endorsed the study design, sample size and powering assumptions, agreed that the Ocular Pain Assessment Survey is appropriate supportive evidence, and aligned on the company’s chemistry, manufacturing and controls strategy without raising material issues—collectively helping to de-risk the path toward a pivotal trial and potential future registration. Urcosimod, which already holds an IND and fast track designation for NCP and has produced positive Phase 2 data, is expected to enter a 120-patient Phase 2b/3 multiple-dose study in the first half of this year, marking a key value-inflection point for OKYO and a potentially important advance in a condition that currently lacks any FDA-approved therapies.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On January 23, 2026, OKYO Pharma announced that the U.S. Food and Drug Administration authorized a single-patient expanded access (compassionate use) Investigational New Drug application for the use of urcosimod (0.05%) in a patient with severe neuropathic corneal pain treated by a physician at the University of South Florida. The authorization allows urcosimod to be used in a setting where there are currently no FDA-approved therapies for NCP and limited treatment options, underscoring both the unmet medical need and the growing clinical interest in the drug’s dual anti-inflammatory and pain-modulating mechanism. The decision builds on urcosimod’s prior IND and fast track status for NCP and follows positive Phase 2 data, as the company prepares to launch a 120-patient Phase 2b/3 multiple-dose study this year, a development that could strengthen OKYO’s position in the ocular pain and inflammatory eye disease market if subsequent trials confirm its efficacy and safety.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On January 5, 2026, OKYO Pharma appointed ophthalmology industry veteran Robert J. Dempsey as Chief Executive Officer and an executive board member, while former CEO Gary S. Jacob, Ph.D., moved into the role of Chief Development Officer and remained on the board. The board-approved leadership transition, effective immediately, is designed to maintain strategic continuity while sharpening OKYO’s commercial and development focus as it advances its flagship drug urcosimod for neuropathic corneal pain and other ocular inflammatory disorders; Dempsey’s track record in launching and commercializing blockbuster eye therapies such as Xiidra and Restasis is expected to strengthen OKYO’s positioning in the ophthalmology market and support the company’s next phase of growth around its planned larger Phase 2 NCP program.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 19, 2025, OKYO Pharma marked its progress in developing treatments for neuropathic corneal pain by having Executive Chairman and Founder Gabriele Cerrone and the management team ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York. The ceremony highlighted the company’s clinical advances with its lead candidate urcosimod, which recently delivered positive Phase 2 results in NCP, demonstrating favorable corneal nerve outcomes and pain reduction in patients facing a debilitating condition without approved therapies. OKYO is leveraging this momentum as it prepares a larger, multicenter Phase 2 trial of urcosimod in NCP, planned to begin in the first quarter of 2026, underscoring its bid to strengthen its position in ocular pain therapeutics and signaling potential long-term implications for patients and investors if subsequent trials confirm these early efficacy signals.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 15, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 24,551 of the company’s ordinary shares on NASDAQ, increasing Cerrone’s total holding to 10,516,297 shares. This acquisition highlights the confidence in OKYO’s ongoing development of urcosimod, a promising treatment for neuropathic corneal pain and dry eye disease, which has shown significant results in Phase 2 trials, potentially enhancing the company’s market position in ophthalmology.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 11, 2025, OKYO Pharma Limited announced new analyses from a Phase 2 clinical trial of urcosimod, showing positive results in treating neuropathic corneal pain (NCP). The trial demonstrated that patients treated with 0.05% urcosimod experienced not only a reduction in pain but also favorable changes in corneal nerve structure, unlike the placebo group. These findings suggest urcosimod’s potential as a first-in-class therapeutic approach for NCP, highlighting its promise in restoring corneal nerve health and supporting further development.
The most recent analyst rating on (OKYO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
On December 3, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 27,051 of the company’s ordinary shares on NASDAQ, increasing his total holdings to 10,491,746 shares. This acquisition underscores confidence in OKYO’s strategic direction, particularly as it advances urcosimod, which recently completed a Phase 2 trial for neuropathic corneal pain, potentially strengthening its market position in the ophthalmology sector.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.